Refractory Restless Leg Syndrome (Investigational Adjunct)

Investigational adjunct for refractory restless leg syndrome after iron and pharmacologic optimization; case reports only.

Tier C — InvestigationalInvestigationalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patient Summary

Is this FDA-cleared for this use?: Not FDA-cleared for refractory restless leg syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
What evidence exists?: Tier C (investigational). No controlled trials. Evidence-based first-line management of RLS is iron repletion when ferritin is below 75-100 ng/mL (iron deficiency is the most common reversible cause), avoidance of triggers (caffeine, alcohol, SSRIs, antihistamines), and pharmacotherapy with gabapentin enacarbil or pregabalin (now preferred over dopamine agonists due to augmentation risk). Refractory cases may benefit from low-dose opioids under specialist supervision.
Main risks: Bleeding from each bite site for 6 to 10 hours after the leech detaches
Iron-deficiency anemia from cumulative blood loss across multiple sessions
Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
Local pain, bruising, swelling, or itching for 1 to 3 days after each session
Worsening of RLS symptoms acutely from blood-volume change (iron loss in RLS patients is concerning)
Iron-deficiency anemia worsening from session-related blood loss (especially harmful in RLS)
Who should not consider this: Patients without recent ferritin testing (must be above 75-100 ng/mL for RLS)
Patients on dopamine agonist therapy with augmentation symptoms (need taper, not adjunct)
Patients who have not tried gabapentinoids or addressed RLS triggers
Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
People with hemophilia or any other inherited bleeding disorder
Patients with severe anemia (hemoglobin under 10 g/dL)
People with an active infection at the planned application site
What to ask your clinician: Has my ferritin been checked and brought above 75-100 ng/mL with iron supplementation?
Are SSRIs, antihistamines, or other RLS-aggravating medications being managed?
Have I tried gabapentin enacarbil or pregabalin?
How will leech-related blood loss affect my iron status and RLS symptoms?
What is the published evidence for leeches in RLS specifically?
How is dopamine agonist augmentation being managed if I am on one?
When to seek urgent care: Bleeding from a bite site that soaks through more than one dressing per hour
Bleeding that continues more than 24 hours after the leech detached
Spreading redness, warmth, swelling, pus, or red streaks around any bite site
Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
Severe worsening of RLS to the point of inability to sleep or function
New severe daytime sleepiness with falls or accidents

What this does NOT mean

It does not mean leech therapy is FDA-cleared for RLS — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
It does not replace iron repletion, the strongest reversible-cause intervention.
It does not replace gabapentinoid therapy or address dopamine agonist augmentation.
It does not have controlled-trial evidence in RLS.
It may worsen RLS by lowering iron stores through repeated blood loss.

Safety cross-references

Clinical Profile

Category: neurological
ICD-10: G25.81
Safety tier: low

Evidence Summary

Restless leg syndrome (RLS, Willis-Ekbom disease) is a sensorimotor disorder with circadian symptom pattern. AAN and IRLSSG guidance recommends iron repletion when ferritin is below ~75 ng/mL, gabapentin enacarbil and pregabalin as first-line pharmacotherapy (avoiding dopamine agonists at high doses due to augmentation risk), and behavioral measures. Refractory cases may require opioid therapy under specialist supervision. No controlled clinical trial of hirudotherapy for restless leg syndrome has been published; any use is investigational and mechanistic only, and any perceived benefit is likely placebo-dominant. Bleeding risk plus the chronic relapsing-remitting nature of RLS make this a low-priority investigational consideration.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

Krashenyuk AI (2010)0

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Ferritin not yet repleted (correct iron deficiency first)
Secondary RLS from chronic kidney disease or pregnancy (etiology-specific workup)
Augmentation from dopamine agonist (taper dopamine agonist; this is the priority issue)
Placement over varicose veins or great saphenous vein

Related Conditions

Cervical Radiculopathy

Off-label use with one RCT (Michalsen 2018) showing significant pain reduction at 7 days in cervical radiculopathy without surgical indication.

Lumbar Radiculopathy (Sciatica)

Off-label use with controlled trial evidence (n=80) showing leg pain and Oswestry score improvement at 4-12 weeks in non-surgical lumbar disc disease.

Migraine

Investigational use with case-series evidence for reduction of migraine frequency and intensity; mechanism plausible via reduction of cervico-cranial venous congestion.

Tension-Type Headache

Investigational use with small case series suggesting frequency reduction in chronic tension headache via reduction of pericranial muscle tension and venous congestion.